"Receptors, IgE" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Specific molecular sites on the surface of B- and T-lymphocytes which combine with IgEs. Two subclasses exist: low affinity receptors (Fc epsilon RII) and high affinity receptors (Fc epsilon RI).
| Descriptor ID |
D017455
|
| MeSH Number(s) |
D12.776.543.750.705.871.280
|
| Concept/Terms |
Receptors, IgE- Receptors, IgE
- CD23 Antigen
- Antigen, CD23
- Antigens, CD23
- CD23 Antigens
- IgE Receptors
- Immunoglobulin E Receptor
- Receptor, Immunoglobulin E
- Fc Receptors, epsilon
- Receptors, epsilon Fc
- epsilon Fc Receptors
- Fc epsilon Receptors
- epsilon Receptors, Fc
- Receptors, Fc epsilon
- CD 23 Antigens
- Antigens, CD 23
|
Below are MeSH descriptors whose meaning is more general than "Receptors, IgE".
Below are MeSH descriptors whose meaning is more specific than "Receptors, IgE".
This graph shows the total number of publications written about "Receptors, IgE" by people in this website by year, and whether "Receptors, IgE" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 2 | 2 |
| 2001 | 0 | 2 | 2 |
| 2003 | 1 | 2 | 3 |
| 2005 | 1 | 2 | 3 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, IgE" by people in Profiles.
-
Kaplan AP. Basophil histamine release in patients with chronic spontaneous urticaria: Optimize or minimize. J Allergy Clin Immunol. 2019 08; 144(2):622-623.
-
Kaplan AP. Diagnosis, pathogenesis, and treatment of chronic spontaneous urticaria. Allergy Asthma Proc. 2018 May 01; 39(3):184-190.
-
Ndaw VS, Abebayehu D, Spence AJ, Paez PA, Kolawole EM, Taruselli MT, Caslin HL, Chumanevich AP, Paranjape A, Baker B, Barnstein BO, Haque TT, Kiwanuka KN, Oskeritzian CA, Ryan JJ. TGF-ß1 Suppresses IL-33-Induced Mast Cell Function. J Immunol. 2017 08 01; 199(3):866-873.
-
Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017 Apr; 72(4):519-533.
-
Li R, Xie C, Zhang Y, Li B, Donelan W, Li S, Han S, Wang X, Cui T, Tang D. Expression of recombinant human IL-4 in Pichia pastoris and relationship between its glycosylation and biological activity. Protein Expr Purif. 2014 Apr; 96:1-7.
-
Fernando J, Faber TW, Pullen NA, Falanga YT, Kolawole EM, Oskeritzian CA, Barnstein BO, Bandara G, Li G, Schwartz LB, Spiegel S, Straus DB, Conrad DH, Bunting KD, Ryan JJ. Genotype-dependent effects of TGF-ß1 on mast cell function: targeting the Stat5 pathway. J Immunol. 2013 Nov 01; 191(9):4505-13.
-
Wilson ML, Elston DM, Tyler WB, Marks VJ, Ferringer T. Dense lymphocytic infiltrates associated with non-melanoma skin cancer in patients with chronic lymphocytic leukemia. Dermatol Online J. 2010 Mar 15; 16(3):4.
-
Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol. 2008 Sep; 122(3):569-73.
-
Ferrer M, Kaplan AP. Chronic urticaria: what is new, where are we headed. Allergol Immunopathol (Madr). 2007 Mar-Apr; 35(2):57-61.
-
Ryan JJ, Kashyap M, Bailey D, Kennedy S, Speiran K, Brenzovich J, Barnstein B, Oskeritzian C, Gomez G. Mast cell homeostasis: a fundamental aspect of allergic disease. Crit Rev Immunol. 2007; 27(1):15-32.